# Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status

> **NCT00813943** · PHASE2 · COMPLETED · sponsor: **EMD Serono** · enrollment: 265 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Cilengitide (2-times weekly)
- **DRUG:** cilengitide (5-times weekly)
- **DRUG:** Temozolomide
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT00813943
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2013-02
- **Final completion:** 2013-08
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2017-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813943, "Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00813943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*